Aminated β-cyclodextrin-grafted Fe3O4-loaded gambogic acid magnetic nanoparticles: preparation, characterization, and biological evaluation. Issue 47 (29th August 2019)

• Record Type: Journal Article
• Authors: Fang, Wei; Dai, Ya Ji; Wang, Ting; Gao, Hai Tao; Huang, Peng; Yu, Juan; Huang, He Ping; Wang, Dian Lei; Zong, Wei Lu
• Is Part Of: RSC advances. Volume 9:Issue 47(2019)
• Page Start: 27136
• Page End: 27146
• Publication Date: 2019-08-29
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/c9ra04955j
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : Based on aminated β-cyclodextrin (6-NH2 -β-CD)-grafted Fe3 O4 and gambogic acid clathrate complexes, a nanoparticle delivery system was developed with the aim of achieving low irritation, strong targeting and high bioavailability of a gambogic acid magnetic nanopreparation. Abstract : Based on aminated β-cyclodextrin (6-NH2 -β-CD)-grafted Fe3 O4 and gambogic acid (GA) clathrate complexes, a nanoparticle delivery system was developed with the aim to achieve low irritation, strong targeting, and high bioavailability of a gambogic acid magnetic nanopreparation. 6-NH2 -β-CD grafted onto Fe3 O4 MNPs was demonstrated by high-resolution transmission electron microscopy, Fourier transform infrared spectroscopy, X-ray diffraction, zeta potential, and magnetic measurements. The average particle size of the Fe3 O4 @NH2 -β-CD MNPs was 147.4 ± 0.28 nm and the PDI was 0.072 ± 0.013. The encapsulation efficiency, drug loading, zeta potential, and magnetic saturation values of the Fe3 O4 @NH2 -β-CD MNPs were 85.71 ± 3.47%, 4.63 ± 0.04%, −29.3 ± 0.42 mV, and 46.68 emu g −1, respectively. Compared with free GA, the in vitro release profile of GA from Fe3 O4 @NH2 -β-CD MNPs was characterized by two phases: an initial fast release and a delayed-release phase. The Fe3 O4 @NH2 -β-CD MNPs displayed continuously increased cytotoxicity against HL-60 and HepG2 cell lines in 24 h, whereas the carrier Fe3 O4 @NH2 -β-CD MNPs showed almost no cytotoxicity, indicating that the release of GA from the nanoparticles had a sustained profile and Fe3 O4 @NH2 -β-CD MNPs as a tumor tissue-targeted drug delivery system have great potential. Besides, blood vessel irritation tests suggested that the vascular irritation could be reduced by the use of Fe3 O4 @NH2 -β-CD MNPs encapsulation for GA. The t 1/2 and the AUC of the Fe3 O4 @NH2 -β-CD@GA MNPs were found to be higher than those for the GA solution by approximately 2.71-fold and 2.42-fold in a pharmacokinetic study, respectively. The better biocompatibility and the combined properties of specific targeting and complexation ability with hydrophobic drugs make the Fe3 O4 @NH2 -β-CD MNPs an exciting prospect for the targeted delivery of GA.